Stocks · News reference
Merck reported positive clinical trial results for its investigational GLP-1/glucagon receptor co-agonist, efinopegdutide, in treating adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The U.S. Food and Drug Administration has approved Merck KGaA's PIMJETMI (pimicotinib) as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT).
The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.
CytoDyn Inc. announced that its drug leronlimab will be evaluated in a clinical study in combination with Merck's pembrolizumab for metastatic triple-negative breast cancer.
The global nucleic acid labeling market is projected to grow from $1.7 billion in 2025 to $2.8 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in genomics, molecular diagnostics, NGS, and high-throughput laboratory workflows. Key applications include oligonucleotide labeling and in-situ hybridization, with the U.S. and China representing major regional markets.
A new survey from Merck Canada indicates that some Canadian adults are not meeting recommended vaccination schedules.
The Merck Manuals has named Dr. Philip Seo as its new Editor-in-Chief.